COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 3 of 348891 for:    ALL

An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04514367
Recruitment Status : Not yet recruiting
First Posted : August 14, 2020
Last Update Posted : August 14, 2020
Information provided by (Responsible Party):
Annexon, Inc.

Brief Summary:
This study is a multi-center, open label, proof-of-biology study of intravenous (IV) ANX005 in subjects with, or at risk for, manifest Huntington's Disease.

Condition or disease Intervention/treatment Phase
Huntington Disease Drug: ANX005 Phase 2

Detailed Description:

The objective of this study is to evaluate the effects of intravenous ANX005 administered for up to 12 weeks in subjects with, or at risk for, manifest Huntington's Disease.

Subjects will receive induction dosing of ANX005 administered by IV infusion on Days 1 and 5 or 6, followed by maintenance dosing every 2 weeks through Week 10, with follow up visits on Weeks 12, 16 and 24.

All subjects will be contacted (in clinic visit or phone call) 6 months after study completion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: ANX005 administered for up to 12 weeks
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
Estimated Study Start Date : August 2020
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ANX005
Drug: ANX005
Intravenous Infusion

Primary Outcome Measures :
  1. Incidence of treatment emergent adverse events (Safety and Tolerability) of ANX005 [ Time Frame: Up to Week 12 ]
    As measured by incidence of TEAEs, SAEs, AEs related to ANX005, SAEs related to ANX005, Grade 3 or higher AEs, Grade 3 or higher AEs related to ANX005, AEs leading to study or treatment discontinuation.

Secondary Outcome Measures :
  1. Pharmacokinetics (PK) of ANX005 [ Time Frame: Up to Week 12 ]
    As measured by ANX005 serum and cerebrospinal fluid concentrations

  2. Pharmacodynamics (PD) effects of ANX005 [ Time Frame: Up to Week 12 ]
    As measured by C1q, C4a, and NfL blood and cerebrospinal fluid concentrations

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of or at risk for Huntington's disease: Total CAG-Age Product (CAP) score > 400 and UHDRS independence score ≥ 80%.
  2. Able to walk independently and self-sufficient in basic activities of daily living (e.g. eating, dressing, bathing)
  3. All HD concomitant medications stable
  4. If female, must be postmenopausal (for at least 2 years), surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or agree to use highly effective methods of contraception
  5. Males with a woman of childbearing potential partner must agree to use highly effective methods of contraception
  6. Previously vaccinated against encapsulated bacterial pathogens (Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae) or willing to undergo vaccination.
  7. Hemoglobin, bilirubin, and LDH within normal limits.
  8. Able to tolerate EEG and LP procedures.

Exclusion Criteria:

  1. Be at risk of suicide or self-harm within the preceding 12 months
  2. Chorea and/or cognitive deficits severe enough to interfere with study assessments.
  3. Subjects with body weight > 150 kg.
  4. Clinically significant findings on the screening laboratory testing or physical examination that are not specific to HD and may interfere with the conduct of the study or the interpretation of the data or increase subject risk.
  5. Signs and symptoms of, or a diagnosis consistent with a chronic autoimmune disorder and/or an ANA titer ≥ 1:160.
  6. History of previous infusion reactions, sensitivities, allergic, or anaphylactic reactions to previous medication infusions.
  7. Receipt of an experimental agent within 60 days or five half-lives prior to Screening or anytime over the duration of this study.
  8. Prior treatment with any monoclonal antibody
  9. Presence of an implanted deep brain stimulation device.
  10. Any history of gene therapy, RNA or DNA targeted HD specific investigational agents such as antisense oligonucleotides, cell transplantation or any experimental brain surgery.
  11. Brain and spinal pathology that may interfere with CSF homeostasis and circulation, increases intracranial pressure (implanted shunt or catheter), malformations or tumor.
  12. Contraindication to undergoing an LP
  13. Hypersensitivity to any of the excipients in the ANX005 drug product
  14. Clinically significant intercurrent illness, medical condition, or medical history (including neurological or mental illness, HIV, any active infection, including Hepatitis B or C) that would jeopardize the safety of the subject, limit participation, or compromise the interpretation of the data derived from the subject
  15. Any known genetic deficiencies of the complement-cascade system.
  16. History of steroid or immunosuppressant medication use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04514367

Layout table for location contacts
Contact: Maria Hernandez 1-650-822-5523
Contact: Marta Schumacher 1-650-822-5507

Layout table for location information
United States, Alabama
Annexon Investigational Site 02
Birmingham, Alabama, United States, 35294
Contact: Maria Hernandez         
United States, California
Annexon Investigational Site 05
Sacramento, California, United States, 95816
Contact: Maria Hernandez         
United States, Colorado
Annexon Investigational Site 03
Englewood, Colorado, United States, 80113
Contact: Maria Hernandez         
United States, District of Columbia
Annexon Investigational Site 04
Washington, District of Columbia, United States, 20057
Contact: Maria Hernandez         
United States, North Carolina
Annexon Investigational Site 07
Durham, North Carolina, United States, 27710
Contact: Maria Hernandez         
United States, Ohio
Annexon Investigational Site 06
Cincinnati, Ohio, United States, 45221
Contact: Maria Hernandez         
United States, Washington
Annexon Investigational Site 08
Kirkland, Washington, United States, 98034
Contact: Maria Hernandez         
Annexon Investigational Site 01
Spokane, Washington, United States, 99202
Contact: Maria Hernandez         
Sponsors and Collaborators
Annexon, Inc.
Layout table for investigator information
Principal Investigator: Rajeev Kumar, MD Rocky Mountain Movement Disorders Center, Englewood, CO
Layout table for additonal information
Responsible Party: Annexon, Inc. Identifier: NCT04514367    
Other Study ID Numbers: ANX005-HD-01
First Posted: August 14, 2020    Key Record Dates
Last Update Posted: August 14, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Neurocognitive Disorders
Mental Disorders